Skip to main content

Advertisement

Table 2 Significance of clinicopathologic parameters and TIL markers for survival

From: Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer

  Univariate p value Multivariate p value
3-Year survival HR (95% CI)
OS
 ECE (Yes vs. No) 46.2% vs. 94.4% 0.000 19.713 (2.594–149.833) 0.004
 N classification (N2/N3 vs. N0/N1) 56.8% vs. 93.4% 0.001 6.473 (1.465–28.609) 0.014
 Margin (Close/Positive vs. Negative) 60.6% vs. 80.8% 0.054   
 Stage (early vs. advanced) 94.7% vs. 66.4% 0.009   
 CD8/FOXP3 (High vs. Low) 87.3% vs. 63.8% 0.006 0.115 (0.017–0.791) 0.028
LRFS
 Differentiation (Moderate/Poor vs. Well) 58.5% vs. 93.3% 0.017 8.679 (1.127–66.871) 0.038
 Gender (Male vs. Female) 70.9% vs. 100% 0.019   
 Margin (Close/Positive vs. Negative) 66.9% vs. 85.8% 0.030   
 ECE (Yes vs. No) 66.4% vs. 79.0% 0.095   
RRFS
 ECE (Yes vs. No) 57.8% vs. 86.0% 0.018 5.268 (1.503–18.466) 0.022
 N classification (N2/N3 vs. N0/N1) 65.2% vs. 81.7% 0.098 16.335 (1.484–179.799) 0.024
 Differentiation (Moderate/Poor vs. Well) 57.7% vs. 88.2% 0.059   
 CD8 (Low vs. High) 65.9% vs. 83.2% 0.069   
 FOXP3 (High vs. low) 49.3% vs. 87.3% 0.000 7.487 (1.786–31.395) 0.006
 CD8/FOXP3 (High vs. Low) 84.1% vs. 61.8% 0.014   
DMFS
 ECE (Yes vs. No) 66.8% vs. 94.4% 0.007 3.929 (0.489–31.590) 0.042
 N classification (N2/N3 vs. N0/N1) 70.3% vs. 97.1% 0.003 2.980 (0.370–24.033) 0.035
 Stage (early vs. advanced) 100% vs. 72.0% 0.005   
 CD3/CD4 (High vs. Low) 70.2% vs. 90.5% 0.026   
 CD4/FOXP3 (High vs. Low) 93.7% vs. 68.4% 0.002 0.032 (0.003–0.384) 0.007
  1. Abbreviation: Advanced stage 4, CI confidence interval, DMFS distant metastasis free survival, Early stage stage 1/2/3, ECE extracapsular extension, HR hazard ratio, LRFS local recurrence free survival, OS overall survival, RRFS regional recurrence free survival